Valuation: Novacyt

Market Cap 33.6M 37.63M 31.04M 28.13M 52.63M 3.57B 53.5M 374M 148M 1.87B 141M 138M 5.9B P/E 2026 *
-
P/E 2027 * -
Enterprise Value 35.56M 39.82M 32.85M 29.77M 55.7M 3.78B 56.62M 395M 157M 1.98B 149M 146M 6.24B EV / Sales 2026 *
1.16x
EV / Sales 2027 * 1.1x
Free-Float
99.83%
Yield 2026 *
-
Yield 2027 * -
1 day+1.20%
1 week-1.38%
Current month-6.36%
1 month-8.22%
3 months+3.92%
6 months+28.39%
Current year+18.54%
1 week 0.46
Extreme 0.455
0.48
1 month 0.44
Extreme 0.445
0.54
Current year 0.29
Extreme 0.29
1.04
1 year 0.29
Extreme 0.29
1.04
3 years 0.29
Extreme 0.29
1.59
5 years 0.29
Extreme 0.29
5.89
10 years 0.06
Extreme 0.0612
13.96
Manager TitleAgeSince
Chief Executive Officer 53 2024-04-30
Director of Finance/CFO 44 2019-12-31
Chief Operating Officer - 2021-10-31
Director TitleAgeSince
Director/Board Member 66 2024-10-30
Chairman 71 2024-09-30
Director/Board Member 53 2023-09-07
Date Insider Type Main position Quantity % Market Cap. Importance
3/30/26 Buy

Chief Executive Officer

1,792 0.0025%
3/30/26 Buy

Chairman

15,228 0.0216%
3/30/26 Buy

Chairman

56,732 0.0803%
Change 5-day change 1-year change 3-year change Capi.($)
+1.20%-1.38%-1.80%-14.17% 37.63M
+2.41%+0.29%+39.41%+72.14% 64.69B
-0.15%+7.50%+11.42%+71.27% 54.78B
+0.57%+4.60%+7.71%+90.93% 53.49B
+0.37%+4.67%+26.68%+49.64% 45.98B
-1.21%+2.32%+21.50%+118.33% 42.94B
-0.37%+5.07%+243.23%+789.58% 40.08B
+0.05%+0.21%+18.06%+48.50% 33.52B
-0.38%+5.68%+38.39%+28.35% 23.67B
+1.19%-4.98%+26.31%-0.76% 23.97B
Average +0.37%+2.03%+43.09%+125.38% 38.32B
Weighted average by Cap. +0.39%+2.73%+46.01%+142.82%

Financials

2026 *2027 *
Net sales 30.52M 34.18M 28.2M 25.55M 47.81M 3.24B 48.6M 339M 134M 1.7B 128M 126M 5.36B 34.86M 39.04M 32.2M 29.18M 54.6M 3.71B 55.5M 388M 153M 1.94B 147M 143M 6.12B
Net income - -
Net Debt 1.96M 2.19M 1.81M 1.64M 3.06M 208M 3.11M 21.74M 8.61M 109M 8.22M 8.05M 343M 4.84M 5.42M 4.47M 4.05M 7.58M 515M 7.71M 53.83M 21.31M 270M 20.35M 19.92M 850M
Projected Income Statement - Annual - Novacyt
Logo Novacyt
Novacyt develops, produces, and sells in vitro and molecular diagnostic products products and instruments, primarily for the genomic medicine sector. Net sales break down by activity as follows: - development of genomic solutions and services (79.7%; Yourgene Health): sale of molecular diagnostic and screening solutions across reproductive health and precision medicine; - manufacturing and sale of reagents and kits for the screening of infectious diseases (20.3%; Primer Design). The group also offers qPCR tests and high-performance workflows for use in the fields of human health, agriculture, veterinary medicine and the environment, aimed at healthcare organisations and the research industry, as well as sequencing services (genome/exome) for the pharmaceutical research sector. Net sales are distributed geographically as follows: France (10.3%), the United Kingdom (20.9%), Europe (20%), Asia/Pacific (28.7%), the Americas (14.5%), Middle East (3.2%) and Africa (2.4%).
Employees
228
Date Price Change Volume
26-10-23 €0.4635 +1.20% 160,585
26-10-22 €0.4580 -1.08% 42,851
26-10-21 €0.4630 +0.54% 37,888
26-10-20 €0.4605 -0.32% 100,540
26-10-19 €0.4620 -1.70% 43,318

Annual profits - Rate of surprise

Rate of surprise - EPS - Annual - Novacyt
  1. Stock Market
  2. Stocks
  3. ALNOV Stock